1-9 of 9
Keywords: Dasatinib
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2025) 148 (1): 105–110.
Published Online: 04 April 2024
... from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Relapse Chronic myeloid leukemia Dasatinib Imatinib Discontinuation With the advent of BCR::ABL1 tyrosine kinase inhibitors (TKIs), the outcome of patients with chronic myeloid...
Journal Articles
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2019) 142 (2): 79–86.
Published Online: 16 May 2019
...Jiaqi Tan; Mengxing Xue; Jinlan Pan; Jiannong Cen; Xiaomei Qi; Ping Liu; Xiaohong Zhao; Pin Wu; Qinrong Wang; Dandan Liu; Yuejun Liu; Suning Chen; Zhi Wang We retrospectively evaluated the efficacy and safety of dasatinib among 48 Chinese patients with chronic phase chronic myeloid leukaemia...
Journal Articles
Acta Haematol (2016) 136 (4): 219–228.
Published Online: 23 September 2016
...Mohamed Shanshal; Andrew Shakespeare; Seshadri Thirumala; Boyd Fenton; Donald P. Quick Dasatinib is a potent inhibitor of the altered tyrosine kinase activity in disease states associated with BCR/ABL1. This agent has been shown to exhibit broad off-target kinase inhibition and immunomodulating...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2015) 134 (4): 248–254.
Published Online: 04 July 2015
... Lorand-Metze; Katia Borgia Barbosa Pagnano Early reduction of BCR-ABL1 transcript levels has been associated with improved outcome in chronic myeloid leukemia (CML) treatment. We evaluated 54 chronic-phase CML patients treated with imatinib who switched therapy to dasatinib (n = 33) or nilotinib (n = 21...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2013) 130 (4): 268–278.
Published Online: 15 August 2013
... according to 3-month BCR-ABL levels across several clinical trials [ 31,41,42,44,45,46,47 ] In a retrospective analysis of the phase III DASISION trial, achieving BCR-ABL transcript levels of ≤10% at 3 months, compared with levels of >10%, in both the dasatinib and imatinib arms, provided...
Journal Articles
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2010) 124 (2): 105–109.
Published Online: 19 August 2010
... month of treatment. During the follow-up, his lymphocyte number doubled in <6 months. Based on previous reports, dasatinib was chosen instead of imatinib. After 6 months of treatment with 100 mg/day of dasatinib, the patient demonstrated a partial response, characterized by the regression of lymph...
Journal Articles